Terns Pharmaceuticals' oral obesity drug shows promise in early study, shares jump

Terns Pharmaceuticals (TERN.O) said its oral obesity drug reduced weight by an average of 4.9% in an early stage study, joining drugmakers vying for a share of the lucrative obesity treatment market and sending its shares up 20% on Monday.